Pharmaceutical intermediates
Dabrafenib Mesylate Intermediates
5 pharmaceutical intermediates for Dabrafenib Mesylate. Indication: Colorectal Cancer; Glioma; Anaplastic Thyroid Cancer; Solid Tumor; Non-Small Cell Lung Cancer; Melanoma; Thyroid Tumor.
About Dabrafenib Mesylate
- Originator
- GlaxoSmithKline (GSK)
- Indication
- Colorectal Cancer; Glioma; Anaplastic Thyroid Cancer; Solid Tumor; Non-Small Cell Lung Cancer; Melanoma; Thyroid Tumor
- Approved Date
- 05/29/2013
- DS/DP
- 06/10/2025
Available intermediates
5 intermediates currently listed for Dabrafenib Mesylate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2,6-Difluorobenzenesulfonyl chloride | 60230-36-6 | / | / |
| Methyl 3-amino-2-fluorobenzoate | 1195768-18-3 | / | / |
| Methyl 3-(2,6-difluorophenylsulfonaMido) -2-fluorobenzoate | 1195768-19-4 | / | / |
| 2-chloro-4-methylpyrimidine | 13036-57-2 | / | / |
| 2,2,2-Trimethylthioacetamide | 630-22-8 | / | / |
Building toward Dabrafenib Mesylate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →